Invitrogen Announces Opening of Hepatocyte Supply Facility in Warrington, UK
Human hepatocytes isolated from liver tissue are used for many biopharmaceutical applications, by researchers investigating liver diseases, and by scientists in the biotech and pharmaceutical sectors trying to predict a compound’s effect on enzyme metabolism in the liver. Many of these kinds of investigations are recommended by the US Food and Drug Administration (FDA) to minimise costly failures during clinical trials.
The new facility in Warrington will supplement the existing facility in North Carolina, USA, and will focus on the regular supply of fresh human hepatocytes to researchers in Europe. Fresh hepatocytes have a short shelf life, but they maintain key functions important for monitoring drug metabolism in vitro.
“Our new facility is part of Life Technologies ongoing commitment to serving the needs of cell biologists in Europe. The Warrington site will help us to ensure rapid access to high quality hepatocytes, for researchers investigating liver function and compound metabolism across a range of market sectors.” said Rob Brainin, Vice-President and General Manager, Invitrogen Hepatic Biology (CellzDirect) at Life Technologies.
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.